Cargando…

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study

BACKGROUND: This study compared the effects of short-term titrated colestilan (a novel non-absorbable, non-calcium, phosphate binder) with placebo, and evaluated the safety and efficacy of colestilan over 1 year compared with sevelamer, in patients with chronic kidney disease (CKD) 5D. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locatelli, Francesco, Spasovski, Goce, Dimkovic, Nada, Wanner, Christoph, Dellanna, Frank, Pontoriero, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	CLINICAL SCIENCE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005560/ https://www.ncbi.nlm.nih.gov/pubmed/24302608 http://dx.doi.org/10.1093/ndt/gft476

Ejemplares similares

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
por: Gutzwiller, Florian S., et al.
Publicado: (2015)

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
por: Rroji, Merita, et al.
Publicado: (2020)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions
por: Ketteler, Markus, et al.
Publicado: (2013)

Symptomatic Hyperphosphataemia Following Phosphate Enema in A Healthy Adult
por: Carl, Ian, et al.
Publicado: (2007)

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
por: Plagemann, Thomas, et al.
Publicado: (2011)

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2023)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

Binding interactions with sevelamer and polystyrene sulfonate in vitro
por: van Berlo‐van de Laar, Inge R.F., et al.
Publicado: (2021)

Ischemic Colitis in Association with Sevelamer Crystals
por: Keri, K. C., et al.
Publicado: (2019)

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Sevelamer Carbonate Crystal-Induced Colitis
por: Lai, T., et al.
Publicado: (2020)

Plant-based dietary approach to stage 3 chronic kidney disease with hyperphosphataemia
por: Campbell, Thomas M, et al.
Publicado: (2019)

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial
por: Smith, Edward R., et al.
Publicado: (2020)

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
por: Bellasi, Antonio, et al.
Publicado: (2019)

The 20th anniversary of BANTAO (Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs)
por: Polenakovic, Momir, et al.
Publicado: (2014)

Sevelamer-Induced Gastrointestinal Injury Presenting as Gastroenteritis
por: Magee, Jared, et al.
Publicado: (2018)

Sevelamer Attenuates Bioprosthetic Heart Valve Calcification
por: Meng, Zhen, et al.
Publicado: (2021)

Complete heart block in a boy with hyperostosis–hyperphosphataemia syndrome: a case report
por: Hosseini, Zahra, et al.
Publicado: (2019)

Author Correction: Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis
por: Fan, Stanley, et al.
Publicado: (2009)

Development and Validation of a Gas Chromatography Method for the Trace Level Determination of Allylamine in Sevelamer Hydrochloride and Sevelamer Carbonate Drug Substances
por: Kadiyala, Raju V. S. N., et al.
Publicado: (2014)

Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
por: Kubotera, Natsuki, et al.
Publicado: (2013)

Colonic Mass Secondary to Sevelamer-Associated Mucosal Injury
por: Bansal, Vishant, et al.
Publicado: (2017)

Sevelamer crystals—an unusual cause of large bowel obstruction
por: Cockrell, Hannah C, et al.
Publicado: (2021)

Improvement in kidney transplantation in the Balkans after the Istanbul Declaration: where do we stand today?
por: Spasovski, Goce, et al.
Publicado: (2016)

An established tradition—the Eighth Congress of the Balkan Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) Belgrade, Serbia, 16–19 September 2007
por: Spasovski, Goce, et al.
Publicado: (2008)

The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu
por: Figurek, Andreja, et al.
Publicado: (2021)

FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia
por: Figurek, Andreja, et al.
Publicado: (2023)

Proteomic Approaches and Potential Applications in Autosomal Dominant Polycystic Kidney Disease and Fabry Disease
por: Rroji, Merita, et al.
Publicado: (2023)

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

ICU-Admission Hyperphosphataemia Is Related to Shock and Tissue Damage, Indicating Injury Severity and Mortality in Polytrauma Patients
por: Rugg, Christopher, et al.
Publicado: (2021)

Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma
por: Iwasaki, Hiroaki
Publicado: (2023)

The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
por: Pierce, David, et al.
Publicado: (2011)

Update and critical appraisal of sevelamer in the management of chronic renal failure
por: Grinfeld, Jacob, et al.
Publicado: (2010)

A case report of sevelamer-associated recto-sigmoid ulcers
por: Tieu, Christina, et al.
Publicado: (2016)

Comparison of Sevelamer and Calcium Carbonate in Prevention of Hypomagnesemia in Hemodialysis Patients
por: Jandaghi, Elahe, et al.
Publicado: (2021)

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients
por: Gonzalez, Elsa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hpm0ivl4ngngn79ku2easqrhh8